Use of a trimethyl-1,3,7 xanthine derivative for the tratment of the memory disturbances and cognitive deficits of aging and alzheimer's disease
CA 2026118 C · Owner: Guillonneau, Claude · Inventors: Mocaer, Elisabeth; Regnier, Gilbert; Kamoun, Annie
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Use, to obtain drugs for the treatment of memory disorders intellectual disorders of senescence and Alzheimer's disease of trimethyl-1,3,7 (diethylaminocarbonyl-4 piperazino-3 propyl -8 xanthine and its physiological tolerable salts by addition.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 25, 1990 and granted July 14, 1998. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended September 25, 2010.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 25, 2012.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.